

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(10) International Publication Number  
**WO 2021/262718 A1**

(43) International Publication Date  
30 December 2021 (30.12.2021)

(51) International Patent Classification:

*A61K 38/17* (2006.01) *A61K 47/68* (2017.01)  
*A61K 38/43* (2006.01) *A61P 11/00* (2006.01)  
*C07K 14/71* (2006.01) *A61P 9/12* (2006.01)

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2021/038482

(22) International Filing Date:

22 June 2021 (22.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

|            |                                |    |
|------------|--------------------------------|----|
| 63/042,722 | 23 June 2020 (23.06.2020)      | US |
| 63/084,409 | 28 September 2020 (28.09.2020) | US |
| 63/112,513 | 11 November 2020 (11.11.2020)  | US |
| 63/188,141 | 13 May 2021 (13.05.2021)       | US |

Published:

— with international search report (Art. 21(3))

(71) Applicant: **ACCELERON PHARMA INC.** [US/US];  
128 Sidney Street, Cambridge, MA 02139 (US).

(72) Inventors: **DE OLIVEIRA PENA, Janethe**; c/o Acceleron Pharma Inc., 128 Sidney Street, Cambridge, MA 02129 (US). **LINDE, Peter**; c/o Acceleron Pharma Inc., 128 Sidney Street, Cambridge, MA 02139 (US). **JOSHI, Sachindra**; c/o Acceleron Pharma Inc., 128 Sidney Street, Cambridge, MA 02139 (US). **LI, Gang**; c/o Acceleron Pharma Inc., 128 Sidney Street, Cambridge, MA 02139 (US). **ANDRE, Patrick**; c/o Acceleron Pharma Inc., 128 Sidney Street, Cambridge, MA 02139 (US). **KUMAR, Ravindra**; c/o Acceleron Pharma Inc., 128 Sidney Street, Cambridge, MA 02139 (US).

(74) Agent: **VARMA, Anita** et al.; White & Case LLP, 75 State Street, Boston, MA 02109 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: **ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH)**

(57) Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of pulmonary arterial hypertension, particularly treating, preventing or reducing the progression rate and/or severity of one or more pulmonary arterial hypertension associated complications.

WO 2021/262718 A1